ABSTRACT
Patients diagnosed with lymph node (LN) metastatic liver cancer face an exceedingly grim prognosis. In-depth analysis of LN metastatic patients' characteristics and tumor cells' interactions with human lymphatic endothelial cells (HLECs), can provide important biological and therapeutic insights. Here we identify at the single-cell level that S100A6 expression differs between primary tumor and their LN metastasis. Of particular significance, we uncovered the disparity in S100A6 expression between tumors and normal tissues is greater in intrahepatic cholangiocarcinoma (ICC) patients, frequently accompanied by LN metastases, than that in hepatocellular carcinoma (HCC), with rare occurrence of LN metastasis. Furthermore, in the infrequent instances of LN metastasis in HCC, heightened S100A6 expression was observed, suggesting a critical role of S100A6 in the process of LN metastasis. Subsequent experiments further uncovered that S100A6 secreted from tumor cells promotes lymphangiogenesis by upregulating the expression and secretion of vascular endothelial growth factor-D (VEGF-D) in HLECs through the RAGE/NF-kB/VEGF-D pathway while overexpression of S100A6 in tumor cells also augmented their migration and invasion. Taken together, these data reveal the dual effects of S100A6 in promoting LN metastasis in liver cancer, thus highlighting its potential as a promising therapeutic target.
Subject(s)
Bile Duct Neoplasms , Carcinoma, Hepatocellular , Liver Neoplasms , Humans , Vascular Endothelial Growth Factor D/metabolism , Vascular Endothelial Growth Factor D/pharmacology , Lymphatic Metastasis , Liver Neoplasms/genetics , Liver Neoplasms/metabolism , NF-kappa B/metabolism , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/metabolism , Endothelial Cells/metabolism , Lymphangiogenesis , Bile Duct Neoplasms/pathology , Bile Ducts, Intrahepatic/pathology , S100 Calcium Binding Protein A6/metabolism , S100 Calcium Binding Protein A6/pharmacology , Cell Cycle Proteins/metabolismABSTRACT
SummaryThe mammalian oviduct plays a pivotal role in the success of early reproductive events. The urokinase plasminogen activator system (uPAS) is present in the bovine oviduct and is involved in extracellular matrix remodelling through plasmin generation. This system can be regulated by several members of the vascular endothelial growth factors (VEGF) and their receptors. In this study, the VEGF-D effect on the regulation of uPAS was evaluated. First, RT-polymerase chain reaction (PCR) analyses were used to evidence the expression of VEGF-D and its receptors in oviductal epithelial cells (BOEC). VEGF-D, VEGFR2 and VEGFR3 transcripts were found in ex vivo and in vitro BOEC, while only VEGFR2 mRNA was present after in vitro conditions. VEGF-D showed a regulatory effect on uPAS gene expression in a dose-dependent manner, inducing an increase in the expression of both uPA and its receptor (uPAR) at 24 h post-induction and decreases in the expression of its inhibitor (PAI-1). In addition, the regulation of cell migration induced by VEGF-D and uPA in BOEC monolayer cultures was analyzed. The wound areas of monolayer cultures incubated with VEGF-D 10 ng/ml or uPA 10 nM were modified and significant differences were found at 24 h for both stimulations. These results indicated that uPAS and VEGF-D systems can modify the arrangement of the bovine oviductal epithelium and contribute to the correct maintenance of the oviductal microenvironment.
Subject(s)
Fallopian Tubes/physiology , Urokinase-Type Plasminogen Activator/metabolism , Vascular Endothelial Growth Factor D/metabolism , Animals , Cattle , Cells, Cultured , Epithelial Cells/physiology , Fallopian Tubes/cytology , Fallopian Tubes/drug effects , Female , Gene Expression Regulation , Plasminogen Activator Inhibitor 1/genetics , Receptors, Urokinase Plasminogen Activator/genetics , Urokinase-Type Plasminogen Activator/genetics , Vascular Endothelial Growth Factor D/genetics , Vascular Endothelial Growth Factor D/pharmacology , Vascular Endothelial Growth Factor Receptor-2/genetics , Vascular Endothelial Growth Factor Receptor-2/metabolism , Vascular Endothelial Growth Factor Receptor-3/genetics , Vascular Endothelial Growth Factor Receptor-3/metabolismABSTRACT
OBJECTIVE: The purpose of this study was to clarify the interaction of vascular endothelial growth factors (VEGFs)-C and -D with cell surface foetal liver kinase-1 (Flk-1) and fms-like tyrosine kinase-4 (Flt-4) receptors in the induction and activity of osteoclasts in cultured human peripheral blood mononuclear cells (PBMCs). DESIGN: PBMCs were cultured on chamber slides or on ivory discs for 2 or 3 weeks in the presence of macrophage-colony stimulating factor (M-CSF), VEGF-A, -C or -D, or placental growth factor (PlGF) with or without receptor activator of nuclear factor kappa-B ligand (RANKL). The number of osteoclasts in each group was counted and the area of ivory resorption was measured. In addition, osteoclast differentiation was further analysed under the same conditions, but with the addition of specific neutralizing antibodies against Flk-1 and Flt-4. RESULTS: RANKL was essential for the induction of osteoclasts in PBMCs. However, significant differences were found in the number of osteoclasts induced by VEGF-A, -C, -D or M-CSF with RANKL compared with control groups lacking or containing RANKL. Blocking of either Flk-1 or Flt-4 resulted in a reduction in the enhancement of osteoclast differentiation in PBMCs by VEGF-C or -D with RANKL. The osteoclasts induced by VEGF-A, -C, -D or M-CSF with RANKL formed significantly larger resorption lacunae than those formed by osteoclasts induced by RANKL alone. CONCLUSIONS: This study showed that VEGF-C and -D play a role in the induction of osteoclast differentiation through both Flk-1 and Flt-4 receptors and influence the area of the ivory resorption in PBMCs.
Subject(s)
Leukocytes, Mononuclear/drug effects , Osteoclasts/drug effects , Vascular Endothelial Growth Factor C/pharmacology , Vascular Endothelial Growth Factor D/pharmacology , Acid Phosphatase/analysis , Biomarkers/analysis , Bone Resorption/pathology , Cell Count , Cell Culture Techniques , Cell Differentiation/drug effects , Cells, Cultured , Growth Substances/pharmacology , Humans , Isoenzymes/analysis , Leukocytes, Mononuclear/physiology , Macrophage Colony-Stimulating Factor/pharmacology , Osteoclasts/physiology , Placenta Growth Factor , Pregnancy Proteins/pharmacology , RANK Ligand/pharmacology , Tartrate-Resistant Acid Phosphatase , Vascular Endothelial Growth Factor A/pharmacology , Vascular Endothelial Growth Factor Receptor-2/drug effects , Vascular Endothelial Growth Factor Receptor-3/drug effectsABSTRACT
Giant cell tumour of bone (GCTB) is a primary bone tumour that contains numerous very large, hyper-nucleated osteoclastic giant cells. Osteoclasts form from CD14+ monocytes and macrophages in the presence of receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage-colony stimulating factor (M-CSF). GCTB contains numerous growth factors, some of which have been reported to influence osteoclastogenesis and resorption. We investigated whether these growth factors are capable of substituting for M-CSF to support osteoclast formation from cultured human monocytes and whether they influence osteoclast cytomorphology and resorption. Vascular endothelial growth factor-A (VEGF-A), VEGF-D, FLT3 ligand (FL), placental growth factor (PlGF) and hepatocyte growth factor (HGF) supported RANKL-induced osteoclastogenesis in the absence of M-CSF, resulting in the formation of numerous TRAP+ multinucleated cells capable of lacunar resorption. Monocytes cultured in the presence of M-CSF, HGF, VEGF-A and RANKL together resulted in the formation of very large, hyper-nucleated (GCTB-like) osteoclasts that were hyper-resorptive. M-CSF and M-CSF substitute growth factors were identified immunohistochemically in GCTB tissue sections and these factors stimulated the resorption of osteoclasts derived from a subset of GCTBs. Our findings indicate that there are growth factors that are capable of substituting for M-CSF to induce human osteoclast formation and that these factors are present in GCTB where they influence osteoclast cytomorphology and have a role in osteoclast formation and resorption activity.
Subject(s)
Bone Neoplasms/metabolism , Giant Cell Tumor of Bone/metabolism , Growth Substances/metabolism , Macrophage Colony-Stimulating Factor/metabolism , Osteoclasts/metabolism , Acid Phosphatase/analysis , Biomarkers, Tumor/analysis , Bone Neoplasms/pathology , Bone Resorption/metabolism , Bone Resorption/pathology , Giant Cell Tumor of Bone/pathology , Giant Cells/metabolism , Giant Cells/pathology , Growth Substances/pharmacology , Hepatocyte Growth Factor/metabolism , Hepatocyte Growth Factor/pharmacology , Humans , Isoenzymes/analysis , Macrophage Colony-Stimulating Factor/pharmacology , Membrane Proteins/metabolism , Membrane Proteins/pharmacology , Monocytes/metabolism , Monocytes/pathology , Osteoclasts/cytology , Placenta Growth Factor , Pregnancy Proteins/metabolism , Pregnancy Proteins/pharmacology , RANK Ligand/metabolism , RANK Ligand/pharmacology , Tartrate-Resistant Acid Phosphatase , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor A/pharmacology , Vascular Endothelial Growth Factor D/metabolism , Vascular Endothelial Growth Factor D/pharmacologyABSTRACT
BACKGROUND: Vascular endothelial growth factor (VEGF)-D is a member of the VEGF family, which can induce angiogenesis and lymphangiogenesis. We have previously demonstrated a role for VEGF-A in cardiac allograft vasculopathy (CAV). Our experiments profile the expression and localization of VEGF-D in human native atherosclerosis (NA), diabetes mellitus with atherosclerosis (DM) and CAV, and we investigate its ability to induce low-density lipoprotein (LDL) permeability in human cardiac microvascular endothelial cells (HCMEC). METHODS: VEGF-D mRNA and protein expression was characterized in coronary arteries and intramyocardial arterioles in NA, DM and CAV using in situ hybridization and immunohistochemical staining. Transendothelial electrical resistance (TER) measurements and immunocytochemical staining for platelet and endothelial cell adhesion molecule-1 and zonula occludens-1 were used to assess endothelial barrier and tight junctional integrity. LDL permeability in response to treatment with VEGF-D was measured using fluorometry in confluent HCMEC. RESULTS: Image quantitation demonstrated significant increases in VEGF-D immunoreactivity in the media of coronary arteries and intramyocardial arterioles of CAV cases, and in the intima and media of coronary arteries of DM cases. Treatment with VEGF-D, in vitro, significantly increased LDL passage through HCMEC monolayers. In conjunction, treatment with VEGF-D significantly decreased TER measurements 2 hours post-treatment and induced the formation of intercellular gaps through an extracellular signal-regulated kinase 1/2 (ERK1/2)-dependent pathway. CONCLUSIONS: VEGF-D is overexpressed in the arteries of CAV and DM cases. Treatment with VEGF-D can disrupt HCMEC tight junctions, resulting in the formation of intercellular gaps, and can also significantly increase LDL permeability through confluent monolayers.
Subject(s)
Atherosclerosis/metabolism , Cell Membrane Permeability/physiology , Coronary Artery Disease/metabolism , Diabetic Angiopathies/metabolism , Endothelium, Vascular/physiopathology , Lipoproteins, LDL/metabolism , Vascular Endothelial Growth Factor D/metabolism , Adolescent , Adult , Arterioles/metabolism , Cell Membrane Permeability/drug effects , Cells, Cultured , Coronary Vessels/metabolism , Endothelium, Vascular/pathology , Female , Humans , In Vitro Techniques , Male , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Tight Junctions/physiology , Tunica Intima/metabolism , Tunica Media/metabolism , Vascular Endothelial Growth Factor D/pharmacology , Young AdultABSTRACT
Lymphangioleiomyomatosis (LAM) is a potentially fatal lung disease characterized by nodules of proliferative smooth muscle-like cells. The exact nature of these LAM cells and their proliferative stimuli are poorly characterized. Herein we report the novel findings that the lymphangiogenic vascular endothelial growth factors (VEGF) C and D induce LAM cell proliferation through activation of their cognate receptor VEGF-R3 and activation of the signaling intermediates Akt/mTOR/S6. Furthermore, we identify expression of the proteoglycan NG2, a marker of immature smooth muscle cells, as a characteristic of LAM cells both in vitro and in human lung tissue. VEGF-C-induced LAM cell proliferation was in part a result of autocrine stimulation that resulted from cross talk with lymphatic endothelial cells. Ultimately, these findings identify the lymphangiogenic VEGF proteins as pathogenic growth factors in LAM disease and at the same time provide a novel pharmacotherapeutic target for a lung disease that to date has no known effective treatment.
Subject(s)
Endothelium/drug effects , Endothelium/metabolism , Lymphangioleiomyomatosis/metabolism , Lymphangioleiomyomatosis/pathology , Vascular Endothelial Growth Factor C/pharmacology , Vascular Endothelial Growth Factor D/pharmacology , Antigens/metabolism , Autocrine Communication/drug effects , Cell Proliferation/drug effects , Endothelial Cells/drug effects , Endothelial Cells/enzymology , Endothelial Cells/pathology , Enzyme Activation/drug effects , Humans , Lymphangioleiomyomatosis/enzymology , Models, Biological , Phosphatidylinositol 3-Kinases/metabolism , Protein Kinases/metabolism , Proteoglycans/metabolism , Ribosomal Protein S6 Kinases/metabolism , Signal Transduction/drug effects , TOR Serine-Threonine Kinases , Tuberous Sclerosis Complex 2 Protein , Tumor Suppressor Proteins/metabolism , Vascular Endothelial Growth Factor Receptor-3/metabolismABSTRACT
Neuronal and vascular cells share common chemical signals. Vascular endothelial growth factor (VEGF)-C and -D and their receptor VEGFR-3/Flt-4 mediate lymphangiogenesis, but they occur also in the brain. Quantitative RT-PCR of mouse brain tissues and cultivated cells showed that the VEGFR-3 gene is highest transcribed in postnatal brain and in glial precursor cells whereas VEGF-C and -D are variably produced by different neuronal and glial cells. In neurospheres (neural stem cells) VEGFR-3 was induced by differentiation with platelet-derived growth factor (PDGF). In functional studies with an A2B5- and nestin-positive, O4-negative murine glial precursor cell line, VEGF-C and -D stimulated phosphorylation of the kinases Erk1/2; this signal transduction was inhibited by UO126. Both peptides induced the proliferation of glial precursor cells which could be inhibited by UO126. Furthermore, VEGF-D considerably enhanced their migration into an open space in a wound-healing assay. These results show that VEGF-C/-D together with its receptor VEGFR-3 provides an auto-/paracrine growth and chemotactic system for glial precursors in the developing brain.
Subject(s)
Cell Differentiation/physiology , Cell Proliferation/drug effects , Neuroglia/metabolism , Stem Cells/metabolism , Vascular Endothelial Growth Factor Receptor-1/metabolism , Animals , Animals, Newborn , Butadienes/pharmacology , Cell Differentiation/drug effects , Cell Line , Cell Line, Tumor , Chemotaxis/drug effects , Chemotaxis/physiology , Enzyme Inhibitors/pharmacology , Mice , Mice, Inbred C57BL , Mitogen-Activated Protein Kinase 3/drug effects , Mitogen-Activated Protein Kinase 3/metabolism , Neuroglia/drug effects , Nitriles/pharmacology , Paracrine Communication/drug effects , Paracrine Communication/physiology , Phosphorylation/drug effects , Platelet-Derived Growth Factor/pharmacology , Signal Transduction/drug effects , Signal Transduction/physiology , Spheroids, Cellular , Stem Cells/drug effects , Vascular Endothelial Growth Factor D/metabolism , Vascular Endothelial Growth Factor D/pharmacology , Vascular Endothelial Growth Factor Receptor-1/drug effectsABSTRACT
BACKGROUND: Reports indicate that vascular endothelial growth factor receptor type 3 (VEGFR3) regulates cellular functions such as invasion, proliferation, and chemo-resistance. However, the exact function of the VEGFR3 signaling axis in prostate epithelial cells is poorly characterized. METHODS: The goal of this study was to evaluate whether TGFbeta1 in combination with VEGFD can promote pre-malignant invasive activities of intermediate basal cells (IBC-10a) isolated from human prostate cancer (Gleason score 6). RESULTS: hTERT immortalized IBC-10a cells normally grew as confluent "cobblestoned" monolayers, but treatment with TGFbeta1 (10 ng/ml for 2-6 hr) dissociated the cell-cell junctions and induced VEGFR3 translocation to the cell surface. This event was not inhibited by 10 microM cycloheximide or puromycin, indicating transcription and protein synthesis were not required. We further discovered that TGFbeta1 in combination with VEGFD induced a significant increase in the invasive activity of IBC-10a cells (>26% and 53% after 24 and 48 hr, respectively) in modified Boyden Chamber assays. TGFbetaRII receptor antibodies specifically blocked TGFbeta1 induction of VEGFR3 translocation to the cell surface and blocked VEGFD-induced invasion. Zymograms revealed that TGFbeta1 (and not VEGFR3) stimulated the secretion of MMP-2 and MMP-9, presumably to promote cell invasion. The cell invasion assays confirmed that antibodies specific for TGFbetaII receptor, MMP-2 and MMP-9 and VEGFR3, independently blocked TGFbeta1-induced invasion. CONCLUSIONS: For the first time, we have demonstrated the mechanism by which TGFbeta1 stimulates VEGFD/VEGFR3 receptor axis activation leading to increased cell migration and invasion by primary intermediate basal cell cultures.
Subject(s)
Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Transforming Growth Factor beta1/metabolism , Vascular Endothelial Growth Factor D/metabolism , Vascular Endothelial Growth Factor Receptor-3/metabolism , Cell Line, Transformed , Chemotaxis/drug effects , Chemotaxis/physiology , Humans , Intercellular Junctions/metabolism , Male , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Prostate/metabolism , Prostate/pathology , Signal Transduction/drug effects , Signal Transduction/physiology , Transforming Growth Factor beta1/pharmacology , Tumor Cells, Cultured , Vascular Endothelial Growth Factor D/pharmacologyABSTRACT
The close association of inflammation, angiogenesis and cancer progression is now highlighted, and in this study we especially focused on a close association of inflammation and lymphangiogenesis. We found that proinflammatory cytokine, interleukin-1beta (IL-1beta), could induce lymphangiogenesis in mouse cornea through enhanced production of potent lymphangiogenic factors, VEGF-A, VEGF-C and VEGF-D. IL-1beta-induced lymphangiogenesis, but not angiogenesis, was inhibited by administration of a selective anti-VEGF receptor-3 (VEGFR-3) neutralizing antibody. And in mouse cornea we observed recruitment of monocyte/macrophages and neutrophils by IL-1beta implanted cornea. Depletion of macrophages by a bisphosphonate encapsulated in liposomes inhibited this IL-1beta-induced lymphangiogenesis and also up-regulation of VEGF-A, VEGF-C, and VEGF-D. Furthermore, IL-1beta-induced lymphangiogenesis and angiogenesis were suppressed by NF-kappaB inhibition with marked suppression of VEGF-A, VEGF-C, and VEGF-D expression.
Subject(s)
Interleukin-1beta/immunology , Keratitis/immunology , Lymphangiogenesis/immunology , Macrophages/immunology , NF-kappa B/metabolism , Vascular Endothelial Growth Factor C/biosynthesis , Vascular Endothelial Growth Factor D/biosynthesis , Animals , Cell Proliferation , Cornea/blood supply , Cornea/drug effects , Cornea/immunology , Diphosphonates/pharmacology , Fibroblast Growth Factor 2/biosynthesis , Fibroblast Growth Factor 2/genetics , Fibroblast Growth Factor 2/pharmacology , Humans , Interleukin-1beta/pharmacology , Lymphangiogenesis/drug effects , Lymphangiogenesis/genetics , Mice , Mice, Inbred C57BL , NF-kappa B/agonists , NF-kappa B/antagonists & inhibitors , Neovascularization, Pathologic/immunology , Vascular Endothelial Growth Factor C/genetics , Vascular Endothelial Growth Factor C/pharmacology , Vascular Endothelial Growth Factor D/genetics , Vascular Endothelial Growth Factor D/pharmacologyABSTRACT
Vascular endothelial growth factor-D (VEGF-D) and vascular endothelial growth factor receptor-2, -3 (VEGFR-2, -3) with their corresponding signaling pathway play significant roles in the development of the embryonic vascular system and pathological lymphangiogenesis. The study was aimed to express and purify the GST-VEGF-D fusion protein, and to explore the angiogenesis effect of VEGF-D. The total RNA was extracted from human fetal lung tissue, and the mature form of VEGF-D was expanded by polymerase chain reaction (PCR), then the plasmid pGEX-5X-1/VEGF-D was reconstructed and the GST-VEGF-D fusion protein expressed in transformed E.coli BL21-DE3. The results showed that the molecular mass of this fusion protein was 38 kD and compassed more than 15% of the total bacteria proteins. The fusion protein was recognized by anti-GST and anti-VEGF-D antibodies. The soluble GST-VEGF-D fusion protein could interact with VEGFR-3/Fc and was able to stimulate the proliferation of human erythroleukemia cell line (HEL) cells. The data of chick embryo chorioallantoic membrane (CAM) experiments indicated that GST-VEGF-D could induce the CAM angiogenesis. It is concluded that the GST-VEGF-D fusion protein with biological activity was successfully expressed, and which may provide an experimental model for the investigation of the VEGF-D-induced angiogenesis and lymphangiogenesis.
Subject(s)
Chorioallantoic Membrane/blood supply , Neovascularization, Physiologic/drug effects , Vascular Endothelial Growth Factor D/pharmacology , Animals , Chick Embryo , Humans , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology , Vascular Endothelial Growth Factor D/biosynthesis , Vascular Endothelial Growth Factor D/geneticsABSTRACT
Vascular endothelial growth factor A (VEGF-A) is a potent inducer of angiogenesis. We now show that VEGF-A-induced adhesion and migration of human endothelial cells are dependent on the integrin alpha9beta1 and that VEGF-A is a direct ligand for this integrin. Adhesion and migration of these cells on the 165 and 121 isoforms of VEGF-A depend on cooperative input from alpha9beta1 and the cognate receptor for VEGF-A, VEGF receptor 2 (VEGF-R2). Unlike alpha3beta1or alphavbeta3 integrins, alpha9beta1 was also found to bind the 121 isoform of VEGF-A. This interaction appears to be biologically significant, because alpha9beta1-blocking antibody dramatically and specifically inhibited angiogenesis induced by VEGF-A165 or -121. Together with our previous findings that alpha9beta1 directly binds to VEGF-C and -D and contributes to lymphangiogenesis, these results identify the integrin alpha9beta1 as a potential pharmacotherapeutic target for inhibition of pathogenic angiogenesis and lymphangiogenesis.
Subject(s)
Cell Movement/physiology , Endothelial Cells/metabolism , Integrins/metabolism , Neovascularization, Physiologic , Vascular Endothelial Growth Factor A/metabolism , Animals , Antibodies, Monoclonal/pharmacology , Cell Adhesion/drug effects , Cell Adhesion/physiology , Cell Movement/drug effects , Cells, Cultured , Fibroblasts/metabolism , Humans , Integrins/agonists , Mice , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/metabolism , Neovascularization, Physiologic/drug effects , Protein Binding/drug effects , Protein Binding/physiology , Vascular Endothelial Growth Factor A/pharmacology , Vascular Endothelial Growth Factor C/metabolism , Vascular Endothelial Growth Factor C/pharmacology , Vascular Endothelial Growth Factor D/metabolism , Vascular Endothelial Growth Factor D/pharmacology , Vascular Endothelial Growth Factor Receptor-2/metabolismABSTRACT
BACKGROUND: Neointimal inflammation and angiogenesis are important contributors of progression and destabilization of the atherosclerotic plaque. While the role of vascular endothelial growth factor (VEGF) and its receptors VEGF-R1 (Flt-1) and VEGF-R2 (Flk-1) in this process has clearly been defined, expression of the VEGF-R3 (Flt-4) has only been documented on lymphatic and tumor endothelium. This study examined Flt-4 expression in human atherosclerotic plaque and explored its implications for atherosclerotic disease. METHODS AND RESULTS: Carotid artery thrombendartherectomy specimens from 10 patients with unstable plaque were stained for Flt-4 and its specific growth factors VEGF-C and VEGF-D. Microvascular endothelial cells (MVEC) stained positive for VEGF-C and -D, but not for Flt-4. Interestingly, macrophages within inflammatory perivascular regions coexpressed Flt-4, VEGF-C and VEGF-D. In vitro studies confirmed the expression of Flt-4, VEGF-C and VEGF-D in human monocytes and cultured macrophages. Treatment of macrophages with VEGF-D induced apoptosis as determined by annexin V staining, by immunoblotting of activated caspase 3, and by the ratio of Bcl-2/Bax as well as by DNA fragmentation. Immunohistochemical studies of advanced human carotid atherosclerotic plaque confirmed the coexpression of Flt-4 with activated caspase 3 and TUNEL staining in macrophages, indicating an ongoing apoptotic process. CONCLUSION: Human monocytes/macrophages express VEGF-C and -D and their receptor Flt-4 in vitro and in vivo within advanced atherosclerotic lesions. Flt-4, in turn, mediates monocyte/macrophage apoptosis and may this way alter plaque stability.
Subject(s)
Carotid Artery Diseases/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Macrophages/metabolism , Signal Transduction/physiology , Vascular Endothelial Growth Factor Receptor-3/physiology , Aged , Aged, 80 and over , Apoptosis/drug effects , Blotting, Western , Carotid Arteries/metabolism , Carotid Arteries/pathology , Caspase 3/metabolism , Cell Line , Cells, Cultured , DNA Fragmentation , Female , Humans , Immunohistochemistry , Intercellular Signaling Peptides and Proteins/analysis , Macrophages/pathology , Male , Microscopy, Fluorescence , Middle Aged , Reverse Transcriptase Polymerase Chain Reaction , Vascular Endothelial Growth Factor C/metabolism , Vascular Endothelial Growth Factor C/pharmacology , Vascular Endothelial Growth Factor D/metabolism , Vascular Endothelial Growth Factor D/pharmacology , Vascular Endothelial Growth Factor Receptor-3/analysisABSTRACT
Vascular endothelial growth factor (VEGF)-D is a member of the VEGF family of angiogenic growth factors that recognizes and activates the vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3 on blood and/or lymphatic vessels. We show that in the long bones of newborn mice, VEGF-D and VEGFR-3 are expressed in the osteoblasts of the growing plate. The treatment of primary human osteoblasts with recombinant VEGF-D induces the expression of osteocalcin and the formation of mineralized nodules in a dose-dependent manner. A monoclonal neutralizing antibody, anti-VEGF-D, or silencing of VEGFR-3 by lentiviral-mediated expression of VEGFR-3 small hairpin RNA affects VEGF-D-dependent osteocalcin expression and nodule formation. Moreover, in primary human osteoblasts, VEGF-D expression is under the control of VEGF, and inhibition of VEGF-D/VEGFR-3 signaling, by monoclonal antibodies or VEGFR-3 silencing, affects VEGF-dependent osteoblast differentiation. These experiments establish that VEGF-D/VEGFR-3 signaling plays a critical role in osteoblast maturation and suggest that VEGF-D is a downstream effector of VEGF in osteogenesis.
Subject(s)
Osteoblasts/cytology , Osteoblasts/physiology , Osteogenesis/physiology , Vascular Endothelial Growth Factor D/metabolism , Vascular Endothelial Growth Factor Receptor-3/metabolism , Aged , Animals , Animals, Newborn , Cell Differentiation/physiology , Cells, Cultured , Endothelium, Vascular/cytology , Female , Humans , Male , Mice , Middle Aged , Osteocalcin/genetics , RNA, Small Interfering , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Signal Transduction/drug effects , Signal Transduction/physiology , Umbilical Veins/cytology , Vascular Endothelial Growth Factor D/genetics , Vascular Endothelial Growth Factor D/pharmacology , Vascular Endothelial Growth Factor Receptor-3/geneticsABSTRACT
Spatio-temporal studies on the growth of capillary blood vessels and capillary lymphatic vessels in tissue remodeling have suggested that lymphangiogenesis is angiogenesis-dependent. We revisited this concept by using fibroblast growth factor 2 (FGF-2) (80 ng) to stimulate the growth of both vessel types in the mouse cornea. When we lowered the dose of FGF-2 in the cornea 6.4-fold (12.5 ng), the primary response was lymphangiogenic. Further investigation revealed that vascular endothelial growth factor-C and -D are required for this apparent lymphangiogenic property of FGF-2, and when the small amount of accompanying angiogenesis was completely suppressed, lymphangiogenesis remained unaffected. Our findings demonstrate that there is a dose-dependent response of FGF-2 for lymphangiogenesis, and lymphangiogenesis can occur in the absence of a preexisting or developing vascular bed, i.e., in the absence of angiogenesis, in the mouse cornea.
Subject(s)
Fibroblast Growth Factor 2/pharmacology , Lymphangiogenesis/drug effects , Animals , Cell Division/drug effects , Cell Movement/drug effects , Cornea/blood supply , Cornea/physiology , Corneal Neovascularization , Dose-Response Relationship, Drug , Endothelial Cells/cytology , Endothelial Cells/drug effects , Male , Mice , Mice, Inbred Strains , Neovascularization, Physiologic/drug effects , Vascular Endothelial Growth Factor C/pharmacology , Vascular Endothelial Growth Factor D/pharmacologySubject(s)
Colorectal Neoplasms/blood supply , Colorectal Neoplasms/physiopathology , Neovascularization, Pathologic , Vascular Endothelial Growth Factor C/pharmacology , Vascular Endothelial Growth Factor D/pharmacology , Vascular Endothelial Growth Factor Receptor-2/physiology , Humans , Immunohistochemistry , Ligands , Neovascularization, Pathologic/physiopathology , Vascular Endothelial Growth Factor C/biosynthesis , Vascular Endothelial Growth Factor D/biosynthesisABSTRACT
Vascular endothelial growth factor (VEGF)-D binds to VEGF receptors (VEGFR) VEGFR2/KDR and VEGFR3/Flt4, but the signaling mechanisms mediating its biological activities in endothelial cells are poorly understood. Here we investigated the mechanism of action of VEGF-D, and we compared the signaling pathways and biological responses induced by VEGF-D and VEGF-A in endothelial cells. VEGF-D induced KDR and phospholipase C-gamma tyrosine phosphorylation more slowly and less effectively than VEGF-A at early times but had a more sustained effect and was as effective as VEGF-A after 60 min. VEGF-D activated extracellular signal-regulated protein kinases 1 and 2 with similar efficacy but slower kinetics compared with VEGF-A, and this effect was blocked by inhibitors of protein kinase C and mitogen-activated protein kinase kinase. In contrast to VEGF-A, VEGF-D weakly stimulated prostacyclin production and gene expression, had little effect on cell proliferation, and stimulated a smaller and more transient increase in intracellular [Ca(2+)]. VEGF-D induced strong but more transient phosphatidylinositol 3-kinase (PI3K)-mediated Akt activation and increased PI3K-dependent endothelial nitric-oxide synthase phosphorylation and cell survival more weakly. VEGF-D stimulated chemotaxis via a PI3K/Akt- and endothelial nitric-oxide synthase-dependent pathway, enhanced protein kinase C- and PI3K-dependent endothelial tubulogenesis, and stimulated angiogenesis in a mouse sponge implant model less effectively than VEGF-A. VEGF-D-induced signaling and biological effects were blocked by the KDR inhibitor SU5614. The finding that differential KDR activation by VEGF-A and VEGF-D has distinct consequences for endothelial signaling and function has important implications for understanding how multiple ligands for the same VEGF receptors can generate ligand-specific biological responses.
Subject(s)
Endothelium, Vascular/physiology , Signal Transduction/physiology , Vascular Endothelial Growth Factor A/physiology , Vascular Endothelial Growth Factor D/physiology , Vascular Endothelial Growth Factor Receptor-2/physiology , Animals , Humans , Indoles/pharmacology , Mice , Neovascularization, Physiologic/physiology , Vascular Endothelial Growth Factor A/pharmacology , Vascular Endothelial Growth Factor D/pharmacology , Vascular Endothelial Growth Factor Receptor-2/agonists , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitorsABSTRACT
Advances in surgical treatment, including sentinel lymphadenectomy, permit the pathologic staging of regional lymph nodes most likely to contain metastasis by identifying afferent lymphatic channels, which specifically drain the primary tumor site. Recently, a new member of the angiogenic molecule in VEGF family, VEGF-D, has been identified that induces lymphangiogenesis via high-affinity binding to VEGFR-3. VEGF-D is predominantly expressed in lymphatic endothelium. We have previously developed a novel method for the isolation of anatomically-defined lymphatic endothelial cells (LECs) from human sentinel lymphatic channel during SLN biopsy. The effect of VEGF-D on the extracellular signal-regulated kinases (Erk)-1/2 and Akt signaling pathway was examined by Western blot analysis. VEGF-D (500 ng/ml) apparently upregulated phospho-p44/phospho-p42 activity in human isolated LECs by Western blot analysis, while phospho-Akt activity was not at all changed by VEGF-D exposure without the change of total p44/p42 and Akt expression. U0126 (20 microM), the MEK1/2 inhibitor, could completely block the VEGF-D induced phospholylation of Erk1/2 signaling pathway. These data demonstrate that VEGF-D induces p44/p42 in human LECs and suggests that this signaling pathway activation may be important in LEC biology and lymphoangiogenesis, which may lead to the progression of new strategies of cancer treatment.